CN115487206A - Method for relieving poor development of tibial cartilage of broiler chicken by morinda officinalis polysaccharide and application of morinda officinalis polysaccharide - Google Patents
Method for relieving poor development of tibial cartilage of broiler chicken by morinda officinalis polysaccharide and application of morinda officinalis polysaccharide Download PDFInfo
- Publication number
- CN115487206A CN115487206A CN202211245466.9A CN202211245466A CN115487206A CN 115487206 A CN115487206 A CN 115487206A CN 202211245466 A CN202211245466 A CN 202211245466A CN 115487206 A CN115487206 A CN 115487206A
- Authority
- CN
- China
- Prior art keywords
- broiler
- group
- mop
- tibial
- broiler chicken
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 125
- 150000004676 glycans Chemical class 0.000 title claims abstract description 31
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 31
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 31
- 241000096284 Gynochthodes officinalis Species 0.000 title claims abstract description 27
- 210000000845 cartilage Anatomy 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims description 26
- 238000011161 development Methods 0.000 title description 9
- 210000002303 tibia Anatomy 0.000 claims abstract description 31
- 210000004349 growth plate Anatomy 0.000 claims abstract description 29
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000011575 calcium Substances 0.000 claims abstract description 18
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 18
- 230000000968 intestinal effect Effects 0.000 claims abstract description 16
- 206010058314 Dysplasia Diseases 0.000 claims abstract description 11
- 230000003647 oxidation Effects 0.000 claims abstract description 9
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 16
- 229910052698 phosphorus Inorganic materials 0.000 claims description 16
- 239000011574 phosphorus Substances 0.000 claims description 16
- KUAZQDVKQLNFPE-UHFFFAOYSA-N thiram Chemical compound CN(C)C(=S)SSC(=S)N(C)C KUAZQDVKQLNFPE-UHFFFAOYSA-N 0.000 claims description 14
- 229960002447 thiram Drugs 0.000 claims description 14
- 239000005843 Thiram Substances 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 13
- 235000013330 chicken meat Nutrition 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000009395 breeding Methods 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 244000131360 Morinda citrifolia Species 0.000 claims description 4
- 235000008898 Morinda citrifolia Nutrition 0.000 claims description 4
- 235000017524 noni Nutrition 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 230000019491 signal transduction Effects 0.000 claims description 4
- 239000002956 ash Substances 0.000 claims description 3
- 235000005911 diet Nutrition 0.000 claims description 3
- 230000037213 diet Effects 0.000 claims description 3
- 239000003651 drinking water Substances 0.000 claims description 3
- 235000020188 drinking water Nutrition 0.000 claims description 3
- 210000003462 vein Anatomy 0.000 claims description 3
- 238000010241 blood sampling Methods 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 claims description 2
- 235000021590 normal diet Nutrition 0.000 claims description 2
- 230000022159 cartilage development Effects 0.000 claims 1
- 238000010186 staining Methods 0.000 claims 1
- 241000894006 Bacteria Species 0.000 abstract description 12
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 208000029088 Phosphorus metabolism disease Diseases 0.000 abstract description 4
- 208000022458 calcium metabolism disease Diseases 0.000 abstract description 2
- 208000030175 lameness Diseases 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 description 21
- 230000000694 effects Effects 0.000 description 17
- 239000000203 mixture Substances 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000011164 ossification Effects 0.000 description 8
- 238000010839 reverse transcription Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000186216 Corynebacterium Species 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 229940118019 malondialdehyde Drugs 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 241001202853 Blautia Species 0.000 description 4
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 4
- 101100518985 Gallus gallus PAX1 gene Proteins 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 241000192031 Ruminococcus Species 0.000 description 4
- 230000008468 bone growth Effects 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 235000013594 poultry meat Nutrition 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 241000193798 Aerococcus Species 0.000 description 3
- 241000227342 Candidatus Arthromitus sp. SFB-mouse Species 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 241000186660 Lactobacillus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012154 double-distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000226559 Candidatus Arthromitus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091092584 GDNA Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 102000008108 Osteoprotegerin Human genes 0.000 description 2
- 108010035042 Osteoprotegerin Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- ZQBZAOZWBKABNC-UHFFFAOYSA-N [P].[Ca] Chemical compound [P].[Ca] ZQBZAOZWBKABNC-UHFFFAOYSA-N 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000014461 bone development Effects 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000004767 rumen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010005940 Bone and joint infections Diseases 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- 101100337673 Caenorhabditis elegans gpx-1 gene Proteins 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010050256 Dysstasia Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000000088 Enchondromatosis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 208000026616 Ollier disease Diseases 0.000 description 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
- 241000566145 Otus Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 241000192142 Proteobacteria Species 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 101150086605 Runx2 gene Proteins 0.000 description 1
- 102000002624 Sp7 Transcription Factor Human genes 0.000 description 1
- 108010043267 Sp7 Transcription Factor Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The morinda officinalis polysaccharide can relieve lameness of the broiler caused by the tibial cartilage dysplasia, improves related indexes of the tibia through a BMP/Smads signal path, restores the structure of a tibial growth plate and balances calcium and phosphorus metabolic disorder caused by TD. Meanwhile, the morinda officinalis polysaccharide also improves the oxidation resistance of organisms, improves the structure of intestinal flora of the broiler chickens, improves the abundance of beneficial bacteria and reduces the abundance of harmful bacteria.
Description
Technical Field
The invention relates to a novel method and application of morinda officinalis polysaccharide, in particular to a method for relieving poor development of tibial cartilage of a broiler and application of morinda officinalis polysaccharide.
Background
Tibial Dyschondroplasia (TD) is a common nutritional metabolic leg disease in rapidly-forming poultry. The disease is characterized by avascular and jade-white cartilage wedges formed by the ossification blockage in cartilage and the proliferation of chondrocytes at the metaphysis of tibia, and has the clinical manifestations of listlessness, appetite reduction, unwilling standing, difficult walking, tibial development deformity and the like, which cause the reduction of the production performance and the low immune function of broilers, and can also induce a series of secondary diseases such as chest cyst, fracture, osteomyelitis and the like to influence the body health of the broilers. The disease is firstly discovered and reported in 1965 in a fast-growing broiler chicken by Leach RM and MC Nesheim in the United states, and then is discovered in succession in the breeding process of poultry such as ducks, turkeys and the like. With the development of global economy, the demand of poultry meat and egg products is increased, and in the process of pursuing development quantity, yield and marketing speed, the leg diseases of the broilers are increased due to the limitation of feeding space and the over-high weight increasing speed in an intensive chicken raising mode, so that the serious threat to the health of the broilers is formed, and the global loss is brought to the broiler breeding industry.
At present, no specific medicine which can be widely used for treating TD exists. Previous studies show that the incidence of TD in broiler chickens can be reduced by feeding vitamin C and vitamin D3 and changing the ratio of calcium to phosphorus in the diet. However, because the production period of broiler chickens is short, the metabolism period of medicines is long, the treatment cost is high, and medicines are remained in commercial chickens and are accumulated continuously, how to widely use the medicines to prevent and treat TD is an important problem.
The traditional Chinese medicine has a long application history, and is widely used for preventing and treating diseases due to good curative effect, small toxicity and small side effect. Morinda citrifolia polysaccharide (MOP) is a derivative extracted from Morinda citrifolia, widely distributed in nature, having antioxidant, anti-inflammatory and bone formation promoting effects. Research shows that MOP can effectively improve the bone density of rats with ovariectomy osteoporosis, and has the effect of resisting osteoporosis by regulating the levels of Tumor necrosis factor-alpha (TNF-alpha) and Interleukin-1 (Interleukin-1, IL-1) in the rats. Meanwhile, MOP also has a certain effect on improving the mineral content in ovariectomized rats, and the MOP can improve the contents of bone calcium and bone phosphorus by regulating the levels of nuclear factor-kappa B Receptor activating factors (RANK) and Osteoprotegerin (OPG), so that the effect of reducing the generation of osteoclasts is achieved. MOP may also promote bone formation by modulating the BMP-2/Runx-2/Osterix pathway. In view of the effect of MOP on the bone growth and development of animals, MOP may have certain potential in preventing and treating bone growth and development diseases of broilers.
Disclosure of Invention
Experiments show that MOP can relieve lameness of broiler chickens caused by TD, improve relevant indexes of shin bones through a BMP/Smads signal path, recover the structure of the shin bone growth plate and balance calcium and phosphorus metabolism disorder caused by TD. Meanwhile, the MOP also improves the oxidation resistance of organisms, improves the structure of intestinal flora of the broiler chickens, improves the abundance of beneficial bacteria, reduces the abundance of harmful bacteria, provides a new idea for treating TD, and proves the potential application value of the MOP in preventing and treating TD.
The invention adopts Yang Lingci and morinda officinalis polysaccharide provided by biotechnology limited company, and the morinda officinalis polysaccharide which is a traditional Chinese medicine extract is used for broiler chickens. Preferably, the morinda officinalis how-glucose is administered in an amount of 500mg/kg in drinking water.
The invention utilizes Ai Ba Yijia (Arbor acids, AA) broiler chicken to establish a thiram induced TD model, the TD model is induced by feeding 100mg/kg thiram added feed in the 4 th to 7 th days, and the incidence rate is obviously higher than that caused by daily ration component change, acid-base balance change and other factors. And the TD model induced by thiram can ensure that the broiler chickens are attacked in the same period on one hand and the incidence rate reaches 100 percent on the other hand, thereby providing sufficient and reliable test materials for deeply researching the pathogenesis of the broiler chickens and being used as an ideal test animal model for researching the broiler chickens. The morinda officinalis how polysaccharide is administered in water at a dose of 500mg/kg/d for fourteen consecutive days. Body weight was recorded daily and broiler clinical symptoms were observed. The method comprises the following steps of taking materials after 14 days, recording the weight and length of the tibia and the width of a tibia growth plate, measuring the ash content, calcium content and phosphorus content in the tibia, extracting broiler tibia growth plate RNA, carrying out RT-qPCR to measure the expression level of BMP/Smads related genes, carrying out histopathological examination on the tibia growth plate, measuring the levels of calcium, phosphorus and bone formation marker alkaline phosphatase (ALP) in plasma by adopting blood, and proving that MOP improves the tibia related indexes through a BMP/Smads signal path, restores the tibia growth plate structure and balances the calcium-phosphorus metabolic disorder caused by TD. Through determining the relevant indexes of plasma oxidative stress, the MOP can improve the oxidation resistance of an organism, collects the caeca content of broiler chickens, performs 16s RNA sequencing, performs OUT statistical analysis, alpha diversity analysis, beta diversity analysis and dominant flora analysis on sample intestinal flora, finds that the MOP can be used for TD broiler intestinal flora structure, improves the relevant abundance of beneficial bacteria, reduces the relevant abundance of harmful bacteria, and further regulates and controls the metabolic function of the organism.
Drawings
FIG. 1. Influence of MOP on clinical symptoms and histopathology of TD broiler chickens
(A) The clinical characteristics of the broiler adaptation period, the thiram induction TD period and the MOP treatment period. (B) Tibial and tibial growth plate morphology examination (C) tibial growth plate index and tibial weight index. (D) examination of tibial growth plate histopathology.
FIG. 2 shows the influence of MOP on the ash content, calcium content and phosphorus content of tibia of TD broiler chicken, the calcium and phosphorus level of blood plasma and bone metabolism index.
(A) Calcium, phosphorus and ash contents of tibia on 14 and 21 days. (B) plasma calcium levels. (C) plasma phosphorus levels. (D) plasma ALP levels.
FIG. 3. Influence of MOP on TD broiler BMP/Smads signal pathway
FIG. 4. Influence of MOP on antioxidant capacity of TD broiler chicken
(A) Plasma T-SOD, GSH-Px activity and MDA level. (B) Tibial growth plate SOD, GPX-1 gene expression level
FIG. 5. Influence of MOP on TD broiler intestinal flora
(A) Venn diagram based on OTUs. (B) Beta diversity: PCoA based on Unweighted-UniFrac. (C) Alpha diversity: simpson index, chao1 index, observe _ speces index, shannon index. (D) phylum level intestinal flora composition and relative abundance. (E) genus level intestinal flora composition and relative abundance.
Advantageous effects
1. The invention provides a traditional Chinese medicine extract, namely morinda officinalis polysaccharide, wherein the morinda officinalis polysaccharide is an extract from a traditional Chinese medicine morinda officinalis, is widely distributed in nature, has the effects of resisting oxidation and inflammation and promoting bone formation, and has good curative effect, small toxicity, small side effect and potential clinical treatment value.
2. The in vivo verification proves that the morinda officinalis how polysaccharide has the characteristics of promoting bone growth, resisting oxidation and improving the structure of intestinal flora, can effectively relieve the poor development of tibial cartilage of the broiler chicken, and provides a new idea for preventing and treating TD.
Detailed Description
The specific implementation mode of the invention comprises the following contents:
as a preferable technical scheme, the method comprises a method for improving thiram-induced broiler tibia dysplasia through a BMP/Smads signaling pathway by morinda officinalis polysaccharide and application of the method.
As the preferable technical scheme, the method comprises the steps of improving the antioxidant capacity of TD broiler chickens by morinda officinalis polysaccharides and the application;
as a preferable technical scheme, the method comprises a method for improving the intestinal flora of TD broiler chickens by using morinda officinalis polysaccharides and an application of the morinda officinalis polysaccharides.
Example 1
The method for improving thiram-induced broiler tibia cartilage dysplasia by morinda officinalis polysaccharide through BMP/Smads signal path comprises the following steps:
step one, selection of raw materials and breeding method
Morinda citrifolia polysaccharide (lot number: CY 180812) was purchased from Yang Lingci Yuan Biotechnology, inc. Thiram (tetramethylthiuram disulfide, M03718066) available from shanghai mclin biochemistry ltd. 120 AA chickens (1 day old; 46.96 +/-6.53 g) were selected and obtained from Kyoda poultry industries, inc.
All broilers were housed in standard room temperature and relative humidity light/dark cycle facilities and provided free of water and food. The broiler chickens were randomly divided into 3 groups of 10 chickens each, 4 replicates each, control (CON), thiram-induced TD and MOP treated groups respectively. On the 4 th to 7 th days, the CON group is fed with normal diet, and the TD group and the MOP group are fed with diet added with thiram of 100 mg/kg. On 7-21 days, 500mg/kg of MOP is added into drinking water for the broiler chickens in the MOP treatment group. The test was carried out for a total of 21 days.
Step two, sampling and measuring method
The broiler weight was recorded daily during the test period, 10 chickens per group were sacrificed on days 7, 14 and 21, respectively, by cervical dislocation, and plasma samples were stored at 4 ℃,3000rpm for 10min and-20 ℃ after carotid vein aseptic blood sampling. Tibia length and growth plate width were measured and H & E stained. The right shin bones of 6 broilers in each group were taken and the ash, calcium and phosphorus contents in the shin bones were measured. Plasma calcium, phosphorus and ALP levels were determined by the kit.
Trizol method for extracting tibial growth plate RNA
Preparing at the early stage of the test: instruments such as a mortar, a grinding rod, a surgical scissors and the like for extracting RNA are sterilized by high-pressure steam in an autoclave in advance, and then are added into liquid nitrogen for precooling.
(1) The tibial growth plate tissue was removed from the-80 ℃ freezer, a small amount (soybean size) of the tissue was placed in a mortar and liquid nitrogen was added, ground with a grinding bar, while liquid nitrogen was continuously added to the mortar until the tissue was ground to a powder, and the sample powder was transferred to a 1.5ml enzyme-free centrifuge tube using a small spatula.
(2) 1mL of Trizol solution (the sample is not sufficiently cracked due to too little lysate, and the concentration of the product is reduced) is added into a 1.5mL EP tube, and the mixture is shaken vigorously by using an oscillator or blown and beaten repeatedly by using a pipette gun, inverted, mixed evenly and placed for 5min.
(3) 200ml of chloroform is added into an EP tube, the mixture is stirred and mixed evenly, and the mixture is placed for 5min at room temperature. C,12000/15min.
(4) The supernatant was aspirated by a pipette gun, isopropanol was added, and the mixture was allowed to stand at room temperature for 10min,4. C12000 and 10min.
(5) The supernatant was discarded and 1ml of 75% ethanol was added for washing, and the mixture was flicked and mixed, 4. C7500 rotating for 5min.
(6) And 6, repeating the step.
(7) Standing at room temperature, air drying, adding 20 μ L of RNase-free ddH2O to dissolve the precipitate, and slightly shaking for 3min to dissolve the RNA precipitate completely.
(8) The concentration of RNA was measured using a nucleic acid protein analyzer and reduced to 1000 ng/. Mu.L for ease of subsequent testing and calculation.
Reagent for reverse transcription of RNA into cDNAIII RT SuperMix for qPCR (+ gDNA wiper) was provided by Biotechnology GmbH of Nanjing Nodezam, the reverse transcription system is shown in Table 1-1, and the specific operation steps are as follows:
(2) Reverse transcription to synthesize cDNA
Preparing reverse transcription system according to reverse transcription instruction
1) System for removing genomic DNA
Preparing the following mixed solution in an RNase-free centrifuge tube
TABLE 1-1 degenomic System
Table 1-1 genomic system
Gently blowing and beating with a pipette, mixing, and heating at 42 deg.C for 2min
2) Preparing a reverse transcription reaction system
(1) mu.L of the diluted sample RNA was extracted, and mixed with 4. Mu.L of 4 × mix gDNA in a 1.5mL enzyme-free centrifuge tube, and then water-bathed in a 42 ℃ water bath for 2min.
(2) After the removal, 11. Mu.L of RNase-free ddH2O and 4. Mu.L of 5 × mix qRT were added to a 1.5mL enzyme-free centrifuge tube, and the mixture was water-bathed in a water bath at 37 ℃ for 15min.
(3) Then the mixture is subjected to water bath for 5s in a water bath kettle at 85 ℃.
(4) Finally, 80. Mu.L of RNase-free ddH2O was added for dilution.
TABLE 1-2 reverse transcription System
Table 1-2 reverse transcription system
As shown in figures 1A-C, the broilers of TD group and MOP group are fed with the feed which is added and fully mixed with 100mg/kg thiram on days 3-7, and a TD broiler model is established. After the TD broiler model is established, clinical symptoms of the TD group broilers are manifested by anorexia or abolition, tibial joint swelling, difficulty in standing and walking, severe people cannot walk in a standing way, and the tibial growth plate area of the broilers is obviously thickened, so that white transparent cartilage plugs which are not calcified and vascularized can be seen. The tibial growth plate index of the broiler chickens in the TD group is obviously higher than that of the broiler chickens in the CON group due to the existence of cartilage plugs (p < 0.05). After MOP treatment, the dorking in the MOP group gradually recovers the appetite, the joint swelling is relieved, and the standing and free walking ability is gradually recovered. The structure of the tibia growth plate of the broiler chicken is gradually recovered to be normal, and blood vessels in a proximal hypertrophic area of the tibia are remarkably increased. Meanwhile, the MOP remarkably improves the weight index of the tibia of the broiler chicken (p is less than 0.05), reduces the index of the tibial growth plate of the broiler chicken and gradually approaches to normal.
Histopathology further showed a significant reduction in vascular and chondrocyte numbers, a disorganized chondrocyte distribution, incomplete cell morphology with concomitant nuclear lysis and fragmentation in the tibial growth plate of broilers in the TD group, as shown in fig. 1D. After MOP treatment, the blood vessel infiltration of the tibial growth plate of the broiler chicken is remarkably increased, the chondrocytes are gradually repaired and regenerated, the arrangement is orderly, and only a small amount of mononuclear cells exist. The results show that MOP can restore adverse effects caused by broiler TD by increasing the weight of the tibia, restoring the structure of the tibia growth plate and promoting vascular infiltration of the tibia growth plate and developmental differentiation of chondrocytes.
The results of tibial ash content and inorganic mineral content are shown in fig. 2A, and show that the ash content of the tibia of the broiler chicken in the TD group is significantly lower than that of the broiler chicken in the CON group and the MOP group (p < 0.05) on the 14 th day, and the difference is not significant on the 21 st day. The calcium content of the tibiae of the broilers in the TD group is obviously lower than that of broilers in the CON and MOP groups on 14 days and 21 days (p is less than 0.05). The phosphorus content of the tibia of the broilers in each group has no significant difference. Plasma ALP, calcium and phosphorus levels of broilers in each group were further examined (FIGS. 2B-D). Plasma calcium and ALP levels in broilers in TD were significantly lower than those in CON (p < 0.05) throughout the experimental period. On days 7 and 21, the plasma phosphorus level of the broilers in TD group is significantly higher than that of the broilers in CON group (p < 0.05). After MOP treatment, the plasma calcium and ALP levels of the broilers in the MOP group are both obviously higher than those of the broilers in the TD group (p is less than 0.05), and the plasma phosphorus level of the broilers in the TD group on the 21 st day is obviously lower than that of the broilers in the TD group (p is less than 0.05). The results show that MOP can increase the ash content in the tibia, relieve the calcium-phosphorus metabolic disorder caused by TD, and increase the activity of a bone formation marker ALP, thereby promoting bone formation.
As shown in FIG. 3, the influence of MOP on BMP-2, smad4 and Runx2 gene expression in tibial growth plate of broiler chicken is shown in FIG. 3, and the expression level of BMP-2, smad4 and Runx2 genes in tibial growth plate of broiler chicken in TD group is significantly lower than that of broiler chicken in CON group (p is less than 0.05) in the whole experimental stage. After MOP treatment, the expression levels of BMP-2, smad4 and Runx2 genes of tibial growth plates of the broilers in the MOP group are all obviously higher than those of the broilers in the TD group (p is less than 0.05). The results indicate that MOP promotes bone formation through the BMP/Smads signaling pathway.
Example 2
The method for improving the antioxidant capacity of TD broiler chicken by morinda officinalis polysaccharide comprises the following steps:
step one, selection of raw materials and breeding method
Same as example 1
Step two, sampling and measuring method
10 chickens were sacrificed by cervical dislocation at 7, 14 and 21 days, plasma samples were stored at 4 deg.C, 3000rpm for 10min and-20 deg.C after sterile collection of carotid vein blood, and the activities of Superoxide Dismutase (SOD) and Glutathione peroxidase (GSH-Px) and the content of Malondialdehyde (MDA) in the plasma were measured by ELISA kit. The expression of antioxidant related genes SOD and GPX-1 in the tibial growth plate is detected by RT-qPCR, and the specific steps are the same as the example 1.
The results of the oxidation resistance related indexes in the broiler plasma are shown in fig. 4A, and the results show that the activities of GSH-Px and T-SOD in the broiler plasma of TD group are both obviously lower than those of the broiler chicken of CON group (p is less than 0.05), and the MDA level in the plasma is obviously higher than that of the broiler chicken of CON group (p is less than 0.05) in the whole test period. After MOP treatment, the activities of plasma T-SOD and GSH-Px of the MOP group are both obviously higher than that of broiler chickens in the TD group (p is less than 0.05), while the content of MDA is obviously lower than that of the broiler chickens in the TD group (p is less than 0.05), and the plasma T-SOD and the GSH-Px are restored to the level similar to that of the CON group.
The expression levels of antioxidant-related genes SOD and GPX-1 in tibial growth plates were further determined by RT-qPCR as shown in FIG. 4B. In the whole test stage, the gene expression levels of SOD and GPX-1 genes of tibial growth plates of broilers in TD group are obviously lower than those of broilers in CON group (p is less than 0.05). After MOP treatment, the expression levels of SOD and GPX-1 genes of tibial growth plates of the broilers in the MOP group are obviously higher than those of the broilers in the TD group (p is less than 0.05). The result shows that MOP can reverse the abnormal change of oxidation indexes caused by TD and promote the expression of antioxidant genes, thereby improving the antioxidant capacity of TD broiler chickens.
Example 3
The method for improving TD broiler intestinal flora by using morinda officinalis polysaccharide comprises the following steps:
step one, selection of raw materials and breeding method
Same as example 1
Step two, sampling and measuring method
On day 21, the cecal contents of 4 broilers in each group were collected, stored at-80 ℃, then iced and homogenized separately, and the microbial genomic DNA in the samples was extracted using the QIAamp DNA tool mini kit according to the manufacturer's protocol. To ensure successful isolation of DNA, the concentration and purity of the DNA extract was determined using the Nanodrop instrument to determine whether DNA was successfully isolated and the integrity of the DNA sample was assessed by electrophoresis on a 1% agarose gel. Bacterial 1696 rRNA V3-V4 hypervariable region was PCR amplified with primer 338F (5'-actcctacgggaggcagca-3') and primer 806R (5 '-GGACTACHVGGGTWTCTAAT-3'). The amplificates were purified and quantified using the aggregate AMPure Beads and PicoGreen dsDNA detection kit (Invitrogen, carlsbad, CA, USA). Constructing a DNA library, and sequencing the amplification product on an Illumina Miseq 250 platform. Alpha diversity was evaluated using the Chao1 index, the Observed _ species index, the Simpson index, and the Shannon index. Beta diversity was evaluated using Principal co-ordinates analysis (PCoA).
The effect of morinda officinalis how polysaccharide has on TD broiler intestinal flora is shown in fig. 5, and the results show that Venn graph shows the overlapping condition of OTU distribution among each group, and the results are shown in fig. 5A, 747 OUT distributions are observed in three experimental groups, 457, 537, 311 OUT distributions are respectively found in the cecal contents of broilers of CON group, TD group and MOP group, and the total number of OUT is 163 (fig. 5A). Beta diversity of gut flora was shown by PCoA analysis, and the results showed significant differences in gut flora clustering among the 3 test groups (fig. 5B). The Alpha diversity of intestinal flora is reflected by 4 indexes, i.e., simpson index, chao1 index, observe _ speces index and Shannon index, as shown in fig. 5C, and the results show that there is no significant difference in Alpha diversity of the broiler intestinal microflora of each test group. To analyze the specific changes in the cecal intestinal microflora of broilers in each test group, we analyzed the relative abundance of the dominant flora (10 bacteria before the relative abundance at phylum level and 20 bacteria before the relative abundance at genus level). At the phylum level, the relative abundance of Firmicutes in ceca of broilers in MOP group was significantly increased (p < 0.05) and the relative abundance of Proteobacteria (Protebacteria) was significantly decreased (p < 0.05) compared to broilers in CON and TD groups. The abundance of Actinobacillus in cecum of broiler chickens in TD group is obviously higher than that of broiler chickens in CON and MOP group (p is less than 0.05). The relative abundance of bacteroidetes (bacteriodes) was not significantly different between groups (fig. 5D). On the genus level, compared with the CON group broiler chickens, the TD group broiler caecum has a significantly increased abundance of beneficial bacteria such as Lactobacillus (Lactobacillus), blautia (Blautia), ruminococcus (Ruminococcus) and segmented filamentous bacteria (Candidatus _ Arthromitus) and intestinal membrane barrier, reduces inflammation, provides energy and immune function related to the organism (p < 0.05), aerococcus (Aerococcus) and Corynebacterium (Corynebacterium) cause bone and joint infection, and causes osteomyelitis and suppurative arthritis (p < 0.05), and the MOP group broiler chickens (Blautia), rumen (Ruminococcus) and segmented filamentous bacteria (Candidatus _ Arthromitus) have a significantly increased abundance (p < 0.05), and the group broiler chickens (Blautia), rumen (Ruminococcus) and segmented filamentous bacteria (Candidatus) have a significantly increased abundance of beneficial bacteria such as Lactobacillus < 0.05), aerococcus (aoccus) and Corynebacterium (Corynebacterium) have a significantly decreased abundance (Corynebacterium) and Corynebacterium) as < 0.05. The result shows that MOP can improve the intestinal flora structure of TD broiler chickens, improve the abundance of beneficial bacteria, reduce the abundance of harmful bacteria and further regulate and control the metabolic function of organisms.
It should be noted that the above-mentioned embodiments are exemplary, and that those skilled in the art, having benefit of the present disclosure, may devise various arrangements that are within the scope of the present disclosure and that fall within the scope of the invention. It should be understood by those skilled in the art that the present specification and figures are illustrative only and are not limiting upon the claims. The scope of the invention is defined by the claims and their equivalents.
Claims (8)
1. A method for relieving tibial cartilage dysplasia of broiler chicken is characterized in that morinda officinalis polysaccharide is added into broiler chicken food.
2. The method of alleviating tibial dysplasia in broiler chicken of claim 1, wherein thiram-induced improvement in tibial cartilage development in broiler chickens is induced by morinda citrifolia polysaccharide through BMP/Smads signaling pathway.
3. The method for alleviating tibial dysplasia of broiler chicken of claim 1, which is characterized by the following steps:
step one, selection of raw materials and breeding method
All broilers were housed in standard room temperature and relative humidity light/dark cycle facilities and provided free of water and food. The experiment randomly divided the broilers into 3 groups of 10 chickens each, each group was 4 replicates, respectively control group (CON), thiram induced TD group and MOP treatment group; on the 4 th to 7 th days, the CON group is fed with normal diet, the TD group and the MOP group are fed with diet added with thiram of 100mg/kg, on the 7 th to 21 th days, the MOP treatment group broilers are added with MOP of 500mg/kg in drinking water, and the test is carried out for 21 days.
Step two, sampling and measuring method
The broiler weight was recorded daily during the test period, 10 chickens per group were sacrificed on days 7, 14 and 21, respectively, by cervical dislocation, and plasma samples were stored at 4 ℃,3000rpm for 10min and-20 ℃ after carotid vein aseptic blood sampling. Measuring the length of the tibia and the width of the growth plate and performing H & E staining; taking the right shin bones of 6 broilers in each group, and measuring the contents of ash, calcium and phosphorus in the shin bones; plasma calcium, phosphorus and ALP levels were determined by the kit.
4. An application of radix Morindae officinalis polysaccharide in relieving tibial cartilage dysplasia of broiler chicken is provided.
5. A method for improving the oxidation resistance of broiler chicken with tibial cartilage dysplasia is characterized in that morinda officinalis polysaccharide is added into broiler chicken food.
6. An application of radix Morindae officinalis polysaccharide in improving broiler oxidation resistance of broiler with tibial cartilage dysplasia is provided.
7. A method for improving intestinal flora of broiler chicken with tibial cartilage dysplasia is characterized in that morinda officinalis polysaccharide is added into broiler chicken food.
8. An application of radix Morindae officinalis polysaccharide in improving intestinal flora of broiler with tibial cartilage dysplasia is provided.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211245466.9A CN115487206A (en) | 2022-10-08 | 2022-10-08 | Method for relieving poor development of tibial cartilage of broiler chicken by morinda officinalis polysaccharide and application of morinda officinalis polysaccharide |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211245466.9A CN115487206A (en) | 2022-10-08 | 2022-10-08 | Method for relieving poor development of tibial cartilage of broiler chicken by morinda officinalis polysaccharide and application of morinda officinalis polysaccharide |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115487206A true CN115487206A (en) | 2022-12-20 |
Family
ID=84473892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211245466.9A Pending CN115487206A (en) | 2022-10-08 | 2022-10-08 | Method for relieving poor development of tibial cartilage of broiler chicken by morinda officinalis polysaccharide and application of morinda officinalis polysaccharide |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115487206A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009155755A1 (en) * | 2008-06-26 | 2009-12-30 | 北京同仁堂股份有限公司 | Method for determining the contents of oligosaccharides in morinda officinalis |
CN105267356A (en) * | 2014-06-27 | 2016-01-27 | 广州万正药业有限公司 | Morinda officinalis oligosaccharides and preparation method therefor |
CN107118283A (en) * | 2017-05-26 | 2017-09-01 | 广东药科大学 | Morinda officinalis sugar polymers and its production and use |
-
2022
- 2022-10-08 CN CN202211245466.9A patent/CN115487206A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009155755A1 (en) * | 2008-06-26 | 2009-12-30 | 北京同仁堂股份有限公司 | Method for determining the contents of oligosaccharides in morinda officinalis |
CN105267356A (en) * | 2014-06-27 | 2016-01-27 | 广州万正药业有限公司 | Morinda officinalis oligosaccharides and preparation method therefor |
CN107118283A (en) * | 2017-05-26 | 2017-09-01 | 广东药科大学 | Morinda officinalis sugar polymers and its production and use |
Non-Patent Citations (8)
Title |
---|
ANAN KONG ET AL.: "The fungicide thiram perturbs gut microbiota community and causes lipid metabolism disorder in chickens", 《ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY》, vol. 206, pages 137 - 12 * |
FANG LIU ET AL.: "Lactobacillus rhamnosus JYLR-005 Prevents Thiram-Induced Tibial Dyschondroplasia by Enhancing Bone-Related Growth Performance in Chickens", 《PROBIOTICS AND ANTIMICROBIAL PROTEINS》, pages 1 - 13 * |
SHU-CHENG HUANG ET AL.: "Morinda officinalis polysaccharides improve meat quality by reducing oxidative damage in chickens suffering from tibial dyschondroplasia", 《FOOD CHEMISTRY》, vol. 344, pages 1 - 12 * |
孔安安等: "中药巴戟天对动物骨骼生长影响的研究进展", 《畜牧与饲料科学》, vol. 40, no. 5, pages 73 - 77 * |
孔安安等: "巴戟天多糖对胫骨软骨发育不良的肉鸡生产性能、胫骨指数、胫骨钙磷灰分和血清电解质的影响", 《畜牧与饲料科学》, vol. 40, no. 11, pages 7 - 12 * |
徐婷婷等: "益生菌经肠道菌群调节肉鸡骨代谢的研究进展", 《中国畜牧杂志》, vol. 58, no. 3, pages 31 - 36 * |
曹芹芹等: "福美双对肉鸡股骨生长发育的影响及巴戟天多糖保护效果的研究", 《畜牧与饲料科学》, vol. 42, no. 4, pages 110 - 117 * |
陈彩英等: "巴戟天的药理研究进展", 《中药新药与临床药理》, vol. 20, no. 3, pages 291 - 293 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104546934B (en) | Excrement pair bacteroid is treating or preventing the application in rheumatoid arthritis or its related disease | |
EP2961835B1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
US9758767B2 (en) | Bacteriophage and antibacterial composition comprising the same | |
CN104546935A (en) | Application of bacteroides thetaiotaomicron in treating or preventing rheumatoid arthritis or related diseases thereof | |
EP2961836B1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
Suthongsa et al. | Effects of dietary levels of chito-oligosaccharide on ileal digestibility of nutrients, small intestinal morphology and crypt cell proliferation in weaned pigs | |
EP3130669B1 (en) | Novel bacteriophage and composition containing same | |
CN105324481A (en) | Novel bacteriophage and antibacterial composition comprising the same | |
CN112375712A (en) | Lactococcus lactis and application thereof | |
Xu et al. | Effects of pomegranate (Punica granatum L.) peel on the growth performance and intestinal microbiota of broilers challenged with Escherichia coli | |
Choi et al. | Effects of tannic acid supplementation on growth performance, gut health, and meat production and quality of broiler chickens raised in floor pens for 42 days | |
CN104546938B (en) | Extremely huge Megamonas is treating or preventing the application in rheumatoid arthritis | |
Tuniyazi et al. | Carbonate buffer mixture and fecal microbiota transplantation hold promising therapeutic effects on oligofructose-induced diarrhea in horses | |
CN115487206A (en) | Method for relieving poor development of tibial cartilage of broiler chicken by morinda officinalis polysaccharide and application of morinda officinalis polysaccharide | |
CN106387314B (en) | Application of bacteroides fragilis in animal breeding | |
EP3135761B1 (en) | Novel bacteriophage and composition comprising same | |
CN104546944B (en) | Lactococcus lactis is treating or preventing the application in rheumatoid arthritis or its related disease | |
CN104546947B (en) | Lactobacillus crispatus is treating or preventing the application in rheumatoid arthritis | |
BR112020006192A2 (en) | in-process method for guidance measures against the spread of salmonella and / or against the spread of campylobacter in an animal herd | |
US20110044969A1 (en) | Antimicrobial Agents for the Treatment of Campylobacter Species in the Crop of a Bird | |
Andalib et al. | In vitro and In vivo Effects of Zataria multiflora Hydro-alcoholic Extract on Bovine Escherichia coli | |
CN113368141A (en) | Pharmaceutical composition for preventing and treating porcine envelope virus infectious diseases, preparation method and application of plant extract | |
CN104546939A (en) | Application of dialister invisus in treating or preventing rheumatoid arthritis or related diseases | |
CN104546941B (en) | Actinomyces naeslundii is treating or preventing the application in rheumatoid arthritis or its related disease | |
CN104546936B (en) | Fleck melaninogenicus is treating or preventing the application in rheumatoid arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20221220 |
|
WD01 | Invention patent application deemed withdrawn after publication |